LAMEA Companion Diagnostics Market By Technology (Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology) By Indication (Oncology, Neurology and Other Indications) By Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type)

Market Report Description

The Latin America, Middle East and Africa Companion Diagnostics Market would witness market growth of 20.7% CAGR during the forecast period (2019-2025).

Technological advances have introduced many modifications to the treatment approach against diseases. Companion diagnostics is associated with a growing need for improved personalized patient treatment that provides health care professionals and their patients a favorable outcome of treatment assurance, as opposed to traditional treatment methods. Companion diagnostics will also have a major effect on the area of oncology therapy.

The development of the companion diagnostics industry will be stepping up with increasing cases of adverse drug reaction (ADR). Due to the incompatibility of certain patients with conventional treatment, adverse drug reactions occur and may cause life-threatening results. However, elevated costs of companion diagnostics can to some extent hinder business growth.

Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Click Here For Free Insights

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.

Scope of the Companion Diagnostics Market Analysis

By Technology

• Immunohistochemistry
• Polymerase chain reaction (PCR)
• Next generation sequencing (NGS)
• In Situ Hybridization and
• Other Technology

By Indication

• Oncology
• Neurology and
• Other Indications

By Cancer Type

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Blood Cancer and
• Other Cancer Type

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled

• Agilent Technologies, Inc.
• Almac Group
• ARUP Laboratories, Inc.
• Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
• Danaher Corporation
• Thermo Fisher Scientific, Inc.
• Hologic, Inc.
• Novartis AG
• Illumina, Inc.
• Qiagen N.V.